UbiVac

UbiVac’s lead product, DPV-001 (DRibble), is a first in class DC-targeted complex immune activator and vaccine/combination immunotherapy that is “off-the-shelf” and in a National Cancer Institute-supported Phase II clinical trial for the adjuvant treatment of non-small cell lung cancer (NSCLC). UbiVac’s pipeline of technologies and vaccines level the playing field by arming the immune system with the ability to recognize cancer cells. UbiVac’s DRibble technology can enable all three of these mechanisms of immune-mediated destruction of cancer cells. In collaboration with partners, UbiVac is excited to be initiating combination immunotherapy trials for advanced or metastatic head and neck cancer. UbiVac’s founders have more than 30 years preclinical and clinical experience in Adoptive Cellular Immunotherapy with T and NK cells and are preparing to launch cell-based therapies. UbiVac has unique and disruptive immune educating and activating vaccine technology. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer neoantigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers. UbiVac postulates that by applying machine learning, artificial intelligence, and generative adversarial networks to the analysis of the extensive monitoring data from these ongoing first-in-human trials, new insights will allow future trials to tailor treatment regimens and further improve outcomes of patients with cancer.